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Abstract
In group sequential designs, adjusting for baseline variables and short-term out-
comes can lead to increased power and reduced sample size. We derive formulas for
the precision gain from such variable adjustment using semiparametric estimators for
the average treatment effect, and give new results on what conditions lead to substan-
tial power gains and sample size reductions. The formulas reveal how the impact of
prognostic variables on the precision gain is modified by the number of pipeline partic-
ipants, analysis timing, enrollment rate, and treatment effect heterogeneity, when the
semiparametric estimator uses correctly specified models. Given set prognostic value of
baseline variables and short-term outcomes within each arm, the precision gain is max-
imal when there is no treatment effect heterogeneity. In contrast, a purely predictive
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baseline variable, which only explains treatment effect heterogeneity but is marginally
uncorrelated with the outcome, can lead to no precision gain. The theory is supported
by simulation studies based on data from a trial of a new surgical intervention for
treating stroke.
Keywords: Baseline variable; group sequential design; relative efficiency; semiparamet-
ric estimator; short-term outcome; treatment effect heterogeneity.
1 Introduction
Group sequential designs involve interim analyses that may result in early stopping of trials
for efficacy or futility. We consider designs where the primary outcome is measured at a
fixed time (called the delay) after enrollment. Prior to measuring the primary outcome,
practitioners may also have measured correlated short-term outcomes and baseline variables
of the enrollees. In the MISTIE-II trial (Hanley et al., 2016) evaluating a surgical treatment
for intracerabral hemorrhage, for example, the primary outcome is the modified Rankin
Scale (a score indicating the degree of disability) at 180 days after treatment; the short-term
outcomes are the modified Rankin Scales at 30 days and 90 days after treatment; and the
baseline variables are a set of health-related covariates measured at enrollment.
Because of its potential to increase power and reduce sample size, research has been
focused on adjusting for baseline variables and short-term outcomes in randomized trials
(e.g., Yang and Tsiatis, 2001; Moore and van der Laan, 2009; Stallard, 2010; Hampson and
Jennison, 2013; Paul et al., 2014). However, according to Pocock et al. (2002), where the
authors surveyed 50 clinical trial reports from major medical journals and found that 36 had
used some form of variable adjustment, “the statistical properties of covariate-adjustment
are quite complex and often poorly understood, and there remains confusion as to what is
an appropriate statistical strategy.” A more recent survey also pointed out the confusing
variation that exists in handling of baseline covariates in randomized trials (Austin et al.,
2
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2010). We attempt to resolve this confusion by addressing the following questions: how much
precision gain can be obtained by properly adjusting for baseline variables and short-term
outcomes? What factors impact such precision gain in a group sequential design?
Many variations of doubly-robust estimators have been proposed for use in randomized
trials, as they are more robust to model misspecification than estimators based on paramet-
ric regression models (Robins and Rotnitzky, 1992; Hubbard et al., 2000; van der Laan and
Robins, 2003; Stitelman et al., 2012). Under randomized treatment assignment and indepen-
dent censoring, the doubly-robust estimators are consistent and hence guarantee Type I error
control even with incorrect regression models. They are asymptotically efficient when the
models are correct. In particular, Lu and Tsiatis (2011) and van der Laan and Gruber (2012)
give general approaches for constructing such estimators using longitudinal data. However,
limited research has been done on quantifying the magnitude of the resulting precision and
its relationship to the design characteristics. An exception is Moore et al. (2011), where the
authors attribute the improved estimation efficiency to the correlation between the baseline
variables and the primary outcome, under the setting of a single stage randomized trial.
In this paper, we consider group sequential designs where the short-term outcome and
the primary outcome can be administratively censored. We derive formulas for the precision
gain (measured by the asymptotic relative efficiency against the unadjusted estimator) from
adjusting for baseline variables and short-term outcomes using semiparametric estimators
in randomized trials. Key components of the formulas include the variance explained by
baseline variables, the residual variance explained by short-term outcomes, the proportion
of pipeline participants, and the degree of treatment effect heterogeneity. The formulas can
be used in trial planning to predict the potential precision gain from variable adjustment,
which will translate to reduced sample size. This theory is supported by simulation studies
based on data from the MISTIE Phase II trial, a trial of a new surgical intervention.
We highlight a few implications of the theory. When estimating the mean primary
3
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outcome in one arm, adjusting for strongly prognostic baseline variables would result in
substantial precision gain, but the precision gain from adjusting for a prognostic short-
term outcome can be limited. If at most 1/3 of the enrollees are in the pipeline and have
missing primary outcome, the asymptotic equivalent sample size reduction by adjusting
for prognostic short-term outcomes is at most half of the reduction by adjusting for an
equally prognostic baseline variable, where the sample size reduction is calculated from the
benchmark of doing no variable adjustment. If there is no missing primary outcome (e.g.,
at the end of a single stage trial or at the final analysis of a group sequential design with no
dropouts), adjusting for prognostic short-term outcomes does not contribute precision gain
at all. If there is administrative censoring or dropout (e.g., at an interim analysis of a group
sequential design), adjusting for short-term outcomes can lead to precision gain, but such
gain is generally smaller at later interim analyses, which are the ones that tend to impact
power the most.
A conclusion for mean outcome in one arm does not necessarily imply the same conclu-
sion for the average treatment effect. When estimating the average treatment effect, the
precision gain from adjusting for baseline variables is modified by treatment effect hetero-
geneity. We propose a measure for the degree of treatment effect heterogeneity, defined as the
standardized variation in the treatment effect across different levels of the baseline variable.
Given set prognostic value of baseline variables and short-term outcomes within each arm,
the precision gain is maximal when there is no treatment effect heterogeneity. In contrast, a
purely predictive baseline variable, which only explains treatment effect heterogeneity but is
marginally uncorrelated with the outcome, can lead to no precision gain. The precision gain
from adjusting for short-term outcomes is not modified by treatment effect heterogeneity.
In Section 2, we introduce notation and assumptions. In Section 3, we establish theory
to analyze the precision gain from adjusting for prognostic baseline variables and short-term
outcomes using semiparametric estimators when estimating the mean primary outcome in
4
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one arm. In Section 4, we analyze the precision gain when estimating the average treatment
effect, which is modified by treatment effect heterogeneity. We give an example of efficient
semiparametric estimators in Section 5, which is used as the test statistic in simulation
studies in Section 6. Section 7, with discussion, concludes the paper.
2 Notation and Assumptions
For participant i, denote by Ai the indicator of a binary treatment. Denote by Wi the vector
of baseline variables that are measured before the treatment assignment. Denote by Li the
short-term outcome, which is observed at time dL after the treatment assignment. Denote by
Yi the primary outcome of interest, observed at time dY after the treatment assignment with
dY ≥ dL. When followed up completely, participant i contributes full data (Wi,Ai,Li,Yi).
The goal is to test for positive average treatment effect: H0 : θ≤ 0 versus H1 : θ > 0, with θ
defined as
θ :=E(Y |A= 1)−E(Y |A= 0).
Denote by n the sample size. Assume that {(Wi,Ai,Li,Yi) : 1≤ i≤n} are independent
and identically distributed draws from a joint distribution P0 on (W,A,L,Y ). We assume a
nonparametric model for the joint distribution P0, and we assume A is independent of W .
The semiparametric results in the following sections are with respect to this model. To show
the key idea, we focus on simple cases with univariate and binary L; the results can be easily
generalized to continuous L.
Assume that during the course of the trial participants are continuously enrolled. Since
not all participants have full data observed at an interim analysis, we use CLi and C
Y
i to
denote the missingness status of Li and Yi, respectively: C
L
i = 1 if and only if Li is observed;
CYi = 1 if and only if Yi is observed. Assume that the censoring is monotone: C
L
i ≥CYi
(i.e., observing Yi implies observing Li). At any time, an enrollee has one of the following
5
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three missingness statuses: (i) (CLi ,C
Y
i ) = (0,0): a pipeline participant with only (Wi,Ai)
observed. (ii) (CLi ,C
Y
i ) = (1,0): a pipeline participant with (Wi,Ai,Li) observed (also called
“partially observed”). (iii) (CLi ,C
Y
i ) = (1,1): a participant with (Wi,Ai,Li,Yi) observed (also
called “fully observed”). Assume that independent censoring holds: (CLi ,C
Y
i ) is independent
of Wi, Ai, and the potential outcomes of Li and Yi. An example of independent censoring
is when administrative censoring is the only source of missingness. See Appendix A in
the Supplementary Material for a formulation of the assumptions within causal inference
framework.
The unadjusted estimator for θ is the difference in sample means of the two arms:
∑
iAiC
Y
i Yi∑
iAiC
Y
i
−
∑
i(1−Ai)CYi Yi∑
iAiC
Y
i
.
The unadjusted estimator for mean primary outcome in one arm is the sample mean of that
arm. This is the benchmark against which we will compare the semiparametric estimator.
An estimator θˆ of the parameter θ is consistent and asymptotically normal (CAN) if
√
n(θˆ−θ) d→N(0,σ2), where d→ denotes convergence in distribution. The asymptotic vari-
ance of θˆ is AVar(θˆ) :=σ2. The asymptotic relative efficiency (ARE) between two estimators
θˆ1 and θˆ2 is the inverse of the ratio of their asymptotic variances:
ARE(θˆ1,θˆ2) :=
AVar(θˆ2)
AVar(θˆ1)
.
Consider two Wald tests for H0 : θ= 0 using two CAN estimators θˆ1 and θˆ2 (each test
statistic being the estimator divided by its standard error). The asymptotic relative efficiency
can be interpreted as the limit of the inverse of ratio of the required sample sizes for the
two estimators to achieve a set power (e.g. 80%) at local alternatives (van der Vaart, 2000,
Section 8.2). Hence, we define the asymptotic equivalent reduction in sample size (RedSS)
6
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of θˆ1 compared to θˆ2 as
RedSS(θˆ1,θˆ2) := 1−ARE(θˆ1,θˆ2)−1. (1)
For instance, if ARE(θˆ1,θˆ2) = 1.25, for both estimators to achieve the same power using the
Wald test, θˆ1 only requires 1/1.25 = 80% sample size compared to θˆ2 asymptotically. This
implies that the asymptotic equivalent reduction in sample size is RedSS(θˆ1,θˆ2) = 20%.
3 Precision Gain When Estimating Mean Primary Outcome in One Arm
3.1 Theoretical Limit on the Precision Gain
In this section we focus on estimating the mean outcome in one arm at a time: E(Y |A= a)
for a∈{0,1}. The estimation of the average treatment effect is addressed in Section 4. Given
a∈{0,1}, let Ea(·) and Vara(·) denote E(· |A= a) and Var(· |A= a), respectively. We first
give a decomposition of Vara(Y ).
Lemma 1. Given a∈{0,1}, we have
Vara(Y ) = Vara{Ea(Y |W )}+Vara{Ea(Y |L,W )−Ea(Y |W )}+Vara{Y −Ea(Y |L,W )}.
(2)
Similar to ANOVA where the total variance is decomposed into the within-group variance
and the between-group variance that are orthogonal to each other, Lemma 1 decomposes
the variance of Y into three orthogonal parts: the variation explained by W , the additional
variation explained by L after adjusting for W , and the residual variation.
The following theorem gives the lower bound on the asymptotic variance for all regular
asymptotically linear (RAL) estimators of E(Y |A= a).
Theorem 2. Assume randomization (A⊥ W ), independent censoring on L,Y , and mono-
tone censoring (CL≥CY ). Define pa :=P (A= a) for a∈{0,1}, pl :=P (CL = 1), and py :=
7
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P (CY = 1). Assume 0<pa< 1 and 0<py≤ pl≤ 1. The semiparametric lower bound on the
asymptotic variance of all RAL estimators for E(Y |A= a) is
Vara{Ea(Y |W )}+ 1
papl
Vara{Ea(Y |L,W )−Ea(Y |W )}+ 1
papy
Vara{Y −Ea(Y |L,W )}.
(3)
Theorem 2 is obtained through analyzing the efficient influence function of E(Y |A=
a). No RAL estimator can have asymptotic variance smaller than the bound in (3). The
estimator in van der Laan and Gruber (2012), discussed in Section 5, achieves this variance
lower bound when all working models are correct. When the models are misspecified, the
asymptotic variance becomes (3) plus certain covariance terms. In our experience, such extra
terms are typically small and (3) still serves as a good approximation, as will be seen in the
simulation results in Section 6.
Theorem 2 implies that adjusting for W is more effective in reducing variance bound than
adjusting for L. Equation (3) is the weighted version of the right-hand side of (2), where
without the weight factors (papl)
−1 and (papy)−1 the three terms in (3) sum to Vara(Y ).
Therefore, if the term with a smaller weight gets larger, the term with a larger weight
will become smaller, which implies that the whole sum of (3) will become smaller. In a
randomized trial with pa = 1/2, the second and the third terms in (3) have at least twice the
weight of the first term. This means that when Vara(Y ) is fixed, larger Vara{Ea(Y |W )}
(i.e., having W explain more variation in Y ) reduces the variance lower bound (3). Similarly,
when pl<py (i.e., when there are partially observed participants), having L explain more
variation after accounting for W also reduces the variance lower bound. Because the ordering
of the weights of the first and the second terms in (3) is 1< 1/(papl), making the first term
larger is more effective than making the second term larger in reducing the variance bound.
Theorem 2 suggests the following definition of R-squared, which quantifies the prog-
nostic value of W and L in each arm. For a∈{0,1}, define the proportion of variation in
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Y explained by W within arm a as R2W ;a := Vara{Ea(Y |W )}/Vara(Y ); the proportion of
variation in Y explained by L within arm a as R2L;a := Vara{Ea(Y |L)}/Vara(Y ); the pro-
portion of additional variation in Y explained by L after accounting for W within arm a as
R2L|W ;a := Vara{Ea(Y |L,W )−Ea(Y |W )}/Vara(Y ); the proportion of residual variation in
Y within arm a as R2r;a := Vara{Y −Ea(Y |L,W )}/Vara(Y ). Lemma 1 implies the following
identify:
R2W ;a+R
2
L|W ;a+R
2
r;a = 1, ∀a∈{0,1}. (4)
3.2 Baseline Variables More Useful than Equally Prognostic Short-term Outcomes When
Estimating Mean Primary Outcome in One Arm
In the following, if there exists an RAL estimator that achieves the asymptotic variance lower
bound, we call it the efficient RAL estimator. The following corollary of Theorem 2 gives the
ARE between the efficient RAL estimator and the unadjusted estimator for E(Y |A= a).
Corollary 1. Assume all conditions in Theorem 2 hold. For the estimand E(Y |A= a) with
a∈{0,1}, the asymptotic relative efficiency between the efficient RAL estimator and the
unadjusted estimator is
ARE(efficient,unadjusted) =
1
papyR2W ;a+(py/pl)R
2
L|W ;a+R
2
r;a
. (5)
In addition, given q ∈ [0,1], we have the following.
(i) (Only W is prognostic.) If R2W ;a = q and R
2
L|W ;a = 0, then
ARE(efficient,unadjusted) =
1
papyq+1−q . (6)
9
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(ii) (Only L is prognostic.) If R2W ;a = 0 and R
2
L;a = q, then
ARE(efficient,unadjusted) =
1
(py/pl)q+1−q . (7)
(a) (b)
Figure 1: Asymptotic relative efficiency between the efficient RAL estimator and the un-
adjusted estimator for estimating E(Y |A= a), assuming pa = 1/2. Figure (a) is when only
the baseline variable W is prognostic with R2W ;a = q. Figure (b) is when only the short-term
outcome L is prognostic R2L;a = q.
We plot the ARE in (6) against py and the ARE in (7) against py/pl in Figure 1 for
q= 0.25 and q= 0.10, assuming pa = 0.5. The observation is threefold. First, the precision
gain from adjusting for a prognostic baseline variable decreases with a smaller proportion of
the pipeline participants (i.e., larger py); the precision gain from adjusting for a prognostic
short-term outcome decreases with a smaller proportion of the partially observed participants
(i.e., larger py/pl).
Second, when every participant has primary outcome observed (e.g., at the final analysis
of a group sequential design with no dropouts), adjusting for prognostic baseline variables
10
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still improves estimation precision, but adjusting for prognostic short-term outcomes does
not. This is seen by letting py = pl = 1 in (6) and (7).
Third, for any given (py,pl), adjusting for a prognostic baseline variable alone always
leads to larger precision gain than adjusting for an equally prognostic short-term outcome
alone. To demonstrate this in a simple example, assume pa = 1/2. By the definition of the
asymptotic equivalent reduction in sample size (RedSS) in (1), adjusting for prognostic W
alone with R2W ;a = q yields RedSS = q(1−py/2), and adjusting for prognostic L alone with
R2L;a = q yields RedSS = q(1−py/pl). The ratio of the two RedSSs equals (assuming q > 0)
r=
RedSS from adjusting for prognostic W with R2W ;a = q
RedSS from adjusting for prognostic L with R2L;a = q
=
1−py/2
1−py/pl . (8)
r > 1 means that the sample size reduction from adjusting for a prognostic W is larger than
that from adjusting for an equally prognostic L; r < 1 means the opposite. Figure 2 plots
r against (pl,py) under the constraint 0<py≤ pl≤ 1. For all (pl,py), r > 1. If py≥ 2/3,
r≥ 2. This means that if at most 1/3 of the enrollees are in the pipeline, the sample size
reduction from adjusting for a prognostic short-term outcome alone is at most half of that
from adjusting for an equally prognostic baseline variable alone. Large pl or small py results
in r close to 1, which means that adjusting for W or adjusting for L results in similar sample
size reduction when there are many participants with L observed or few with Y observed.
This usually occurs at early stages of a group sequential design, if the delay of the primary
outcome is long and the delay of the short-term outcome is relatively short.
4 Precision Gain When Estimating Average Treatment Effect
4.1 Theoretical Limit on the Precision Gain
In this section, we assume that the treatment assignment is balanced (i.e., pa = 1/2 for
a∈{0,1}). The following theorem, parallel to Theorem 2, gives the asymptotic variance
11
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Figure 2: Contour plot of r(pl,py), where r is the ratio of the reductions in sample size
when only W is prognostic with R2W ;a = q and when only L is prognostic with R
2
W ;a = q. The
estimand is E(Y |A= a). Assume pa = 1/2.
12
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lower bound for estimating the average treatment effect: E(Y |A= 1)−E(Y |A= 0).
Theorem 3. Under the assumptions in Theorem 2, the semiparametric lower bound on the
asymptotic variance of all RAL estimators for E(Y |A= 1)−E(Y |A= 0) is
Var{E1(Y |W )−E0(Y |W )}+
∑
a∈{0,1}
2
pl
Vara{Ea(Y |L,W )−Ea(Y |W )}
+
∑
a∈{0,1}
2
py
Vara{Y −Ea(Y |L,W )} (9)
The second and third terms in (9) also appear in (3), but the first term in (9) is unique.
Var{E1(Y |W )−E0(Y |W )} can be interpreted as the treatment effect heterogeneity, be-
cause it characterizes the variation in treatment effect across different levels of W . It equals
0 when there is no treatment effect heterogeneity. We define the degree of treatment effect
heterogeneity as its standardized version:
γ=
Var{E1(Y |W )−E0(Y |W )}∑
a∈{0,1}Vara{Y }
. (10)
By definition 0≤ γ≤ 2R2W ; γ= 0 corresponds to no treatment effect heterogeneity.
Similar to the R-squared for one arm defined at the end of Section 3.1, we define the R-
squared for both arms pooled together as follows. Define the pooled proportion of variation
in Y explained by W as
R2W :=
∑
a∈{0,1}Vara{Ea(Y |W )}∑
a∈{0,1}Vara(Y )
;
the pooled proportion of variation in Y explained by L as
R2L :=
∑
a∈{0,1}Vara{Ea(Y |L)}∑
a∈{0,1}Vara(Y )
;
13
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the pooled proportion of additional variation in Y explained by L after accounting for W as
R2L|W :=
∑
a∈{0,1}Vara{Ea(Y |L,W )−Ea(Y |W )}∑
a∈{0,1}Vara(Y )
;
the pooled proportion of residual variation in Y as
R2r :=
∑
a∈{0,1}Vara{Y −Ea(Y |L,W )}∑
a∈{0,1}Vara(Y )
.
Lemma 1 yields
R2W +R
2
L|W +R
2
r = 1.
4.2 Treatment Effect Heterogeneity Impacts Precision Gain When Estimating Average
Treatment Effect
Moore et al. (2011) discussed the impact of prognostic baseline variables on relative efficiency
when estimating the average treatment effect. In this section we generalize their result to
incorporate the short-term outcomes and the proportion of pipeline participants, and analyze
how the treatment effect heterogeneity modified precision gain.
Corollary 2. Suppose all the assumptions in Theorem 2 hold. For the estimand E(Y |A=
1)−E(Y |A= 0), the asymptotic relative efficiency between the efficient RAL estimator and
the unadjusted estimator is
ARE(efficient,unadjusted) =
1
(py/2)γ+(py/pl)R2L|W +R
2
r
. (11)
In addition, given q ∈ [0,1], we have the following.
(i) (Only W is prognostic.) If R2W = q and R
2
L|W = 0, then
ARE(efficient,unadjusted) =
1
(py/2)γ+1−q . (12)
14
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(ii) (Only L is prognostic.) If R2W = 0 and R
2
L = q, then
ARE(efficient,unadjusted) =
1
(py/pl)q+1−q . (13)
Treatment effect heterogeneity modifies the precision gain from adjusting for prognostic
baseline variables when estimating the average treatment effect. By (12), with fixed py
and R2W , smaller treatment effect heterogeneity results in more precision gain. The gain is
maximal when the treatment effect is constant across different levels of W , which happens,
for example, under the sharp null hypothesis. By (13), the precision gain from adjusting
for short-term outcomes is not affected by the treatment effect heterogeneity, since L is
measured post-treatment.
The following corollary gives the ARE when adjusting for baseline variables in two ex-
treme cases.
Corollary 3. Assume all the conditions in Theorem 2 hold. Assume R2W = q for some
q ∈ [0,1] and R2L|W = 0. For the estimand E(Y |A= 1)−E(Y |A= 0), we have the following
result regarding the asymptotic relative efficiency (ARE) between the efficient RAL estimator
and the unadjusted estimator.
(i) (Purely predictive baseline variable.)
If W satisfies Var{E(Y |W,A= 1)−E(Y |W,A= 0)}> 0 and Var{E(Y |W )}= 0, then
ARE(efficient,unadjusted) =
1
1−(1−py)q . (14)
(ii) (Purely prognostic baseline variable.)
If W satisfies Var{E(Y |W,A= 1)−E(Y |W,A= 0)}= 0 and Var{E(Y |W )}> 0, then
ARE(efficient,unadjusted) =
1
1−q . (15)
15
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A baseline variable W satisfying the conditions in Corollary 3(i) is called purely predictive.
A purely predictive baseline variable indicates who benefits from the treatment (i.e., explains
the treatment effect heterogeneity), but it does not explain the variation in Y marginally. For
a purely predictive baseline variable, ARE = 1 in (14) when py = 1. This means that adjusting
for a purely predictive baseline variable results in no precision gain when there is no missing
primary outcome. In extreme situations, a baseline variable can be perfectly correlated with
the outcome within each arm but still contributes nothing to the precision gain. An example
is where W,A are independently distributed as Bernoulli(0.5) and Y =1(A=W ). Hence,
the prognostic value of W within each arm (measured by R2W ;a) does not determine the
precision gain when estimating the average treatment effect; the degree of treatment effect
heterogeneity is also a key factor.
A baseline variable W satisfying the conditions in Corollary 3(ii) is called purely prog-
nostic, because it explains the variation in Y marginally and the treatment effect is constant
across strata of W . For a purely prognostic baseline variable, ARE in (15) does not depend
on py. This is different from (6) for estimating the mean primary outcome in one arm, where
py affects ARE. Such difference is seen in the simulation results in Section 6.4.
5 Semiparametric Efficient Estimator for Variable Adjustment
One semiparametric estimator that could achieve the asymptotic variance lower bounds in
(3) and (9) is the Targeted Minimum Loss Estimator (TMLE) (van der Laan and Gruber,
2012). This estimator builds on the ideas of Robins (2000), Bang and Robins (2005), and
van der Laan and Rubin (2006), and is implemented in the R package ltmle (Schwab et al.,
2014).
Our randomization and independent censoring assumptions imply that the treatment
assignment and the missingness of L and Y are sequentially randomized conditional on the
observed history. This combined with a positivity assumption imply that TMLE is consistent
16
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no matter whether the regression models for L and Y is correct, an implication of TMLE’s
double robustness. When the regression models are correct, TMLE achieves the asymptotic
variance lower bound.
For the binary primary outcome in the MISTIE-II data set, let Qˆ(Zi) denote the pre-
diction of P (Yi = 1) from logistic regression model with regressor Zi. We can estimate the
R-squared for one arm by their empirical versions. For example, R2W ;a can be estimated by
Rˆ2W ;a :=
∑
i:Ai=a
{Qˆ(Ai,Wi)−Qˆ(Ai)}2
/∑
i:Ai=a
{Yi−Qˆ(Ai)}2. The pooled R-squared and the
degree of treatment effect heterogeneity γ can be estimated in a similar way.
6 Simulation
6.1 Trial Example: MISTIE-II
MISTIE-II is a Phase II randomized clinical trial evaluating a new surgical treatment for
intracerebral hemorrhage (ICH). The treatment is called Minimally-Invasive Surgery Plus rt-
PA for Intracerebral Hemorrhage Evacuation, abbreviated as MISTIE (Hanley et al., 2016).
In the MISTIE-II dataset, the primary and short-term outcomes of each participant corre-
spond to the Modified Rankin Scale (mRS) on degree of disability, measured at different times
after treatment. The variables used in this paper are listed in Table 1. The primary outcome
Y is a binary indicator of a successful outcome (mRS≤ 3) at 180 days after treatment. The
short-term outcomes L(1) and L(2) are the indicators of mRS no larger than 4 at 30 and 90
days after treatment, respectively. The cutoff 4 for L(1) and L(2) was chosen, because there
were relatively few participants with mRS 3 or less at 30 or 90 days after treatment. The
treatment assignment indicator A denotes whether a patient is assigned to the new surgical
treatment. Baseline variables W (1)-W (4) are age at enrollment (dichotomized by 65 years),
baseline NIHSS (NIH Stroke Scale total score, quantifying stroke-caused impairment), ICH
(Intracerebral hemorrhage volume), and GCS (Glasgow Coma Scale, a neurological scale of
the conscious state).
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L(1) and L(2) are both used in generating hypothetical patient data, but only L(1) will be
used in constructing the adjusted estimator.
Name Description
W (1) age (years), dichotomized by 65
W (2) baseline NIHSS, continuous
W (3) baseline ICH, continuous
W (4) baseline GCS, continuous
A treatment indicator, 1 being MISTIE
L(1) mRS at 30 days, dichotomized by 4
L(2) mRS at 90 days, dichotomized by 4
Y mRS at 180 days, dichotomized by 3
Table 1: The variables from the MISTIE-II dataset that are used in this paper.
6.2 Group Sequential Design
With the average treatment effect θ defined as θ :=E(Y |A= 1)−E(Y |A= 0), we wanted to
test for H0 : θ≤ 0 versus H1 : θ > 0. The goal of the design was to control Type I error at
0.025 and to have at least 80% power at θ= 0.122, which is the sample average treatment
effect calculated from the 100 participants in the MISTIE-II data set using the unadjusted
estimator.
We used Hampson and Jennison (2013) delayed response group sequential design as the
design for our simulated trials; a brief description follows. With the exception of the final
stage, each stage of the design consists of two analyses: an interim analysis and a decision
analysis. At each interim analysis, a test statistic is calculated using the enrollees’ data (fully
observed and pipeline participants included). Whether to stop the enrollment is determined
based on this test statistic. If the enrollment is not stopped, the decision analysis of that stage
is skipped and the trial proceeds to the interim analysis of the next stage (or the decision
analysis of the final stage, if the next stage is the final stage). Otherwise, if the enrollment is
stopped, the decision analysis of that stage occurs when all the pipeline participants become
18
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fully observed. At the decision analysis, a test statistic is calculated using data of the
enrollees, who are all fully observed. Whether to reject the null hypothesis is determined
based on this test statistic. Details are included in Appendix B.1 in the Supplementary
Material for completeness.
Denote by K the total number of stages if the trial proceeds to the final stage. We
chose K = 5 for the design used in our simulated trials. We generated continuous participant
accrual in the simulation, with a constant enrollment rate of 140 participants per year based
on the projection for the enrollment rate in the MISTIE-III trial (Hanley, 2016). Given
a predetermined maximum sample size nmax, the timing of interim analyses was chosen
such that for 1≤ k≤ 4, at the k-th interim analysis there are (k/K)nmax fully observed
participants. The critical regions for both analyses at each stage were calculated using the
error spending approach presented in Appendix B.2 in the Supplementary Material. We
used f(t) = 0.025min(t2,1) for Type I error spending and g(t) = 0.2min(t2,1) for Type II
error spending, where t denotes the information time. The variance of the test statistic at
each analysis was assumed known.
6.3 Data Generating Distributions for Simulation Study Based on MISTIE-II
The MISTIE-II data set consists of 100 participants with fully observed (W,A,L,Y ). If we
resampled directly from the 100 participants, each simulated participant would have deter-
ministic treatment assignment given his/her baseline variable, especially when the baseline
variables are categorical with many levels or continuous, as is the case here. Such simulation
fails to generate data with the randomization assumption. To overcome this, we used a
resampling-based algorithm to generate hypothetical participants using the MISTIE-II data
set. This algorithm generates simulated trials with the following properties:
(i) The treatment assignment is independent of baseline variables.
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(ii) The average treatment effect of the simulated data equals the unadjusted estimate
using the MISTIE-II data set.
(iii) The relative efficiency between TMLE and the unadjusted estimator is similar to that
of the MISTIE-II data set.
Details of the algorithm are in Appendix C in the Supplementary Material. Briefly, the algo-
rithm ensures property (i) by adding a “twin” with identical baseline variable and opposite
treatment assignment to each participant in the data set. Then it simulates L and Y for
each “twin” using probabilistic methods to ensure properties (ii) and (iii). Properties (ii)
and (iii) enable us to evaluate the power and efficiency gain from variable adjustment in a
realistic setting.
We used the above algorithm and its three variations to generate data under 4 prognostic
settings. prognW,L is the algorithm “as-is”, where both W and L are prognostic. prognW is
the above algorithm followed by resetting L as random draws from its empirical distribution,
in which case only W is prognostic. Similarly, prognL resets W , in which case only L is
prognostic. progn∅ resets both W and L, in which case none of them is prognostic.
The above algorithm generates hypothetical participants with average treatment effect
θ= 0.122, as desired under H1. To generate participants under H0, the algorithm further sets
each Ai to be a random draw from Bernoulli(0.5). Hence, under H1 there is slight treatment
effect heterogeneity with γ= 0.018, and under H0 there is no treatment effect heterogeneity
(γ= 0).
To assess the performance of semiparametric estimators under model misspecification, we
generated the trials using all the variables listed in Table 1, but only used W = (W (1),W (4))
and L=L(1) in fitting TMLE. Table 2 lists the R-squared of the simulated data under H0
and H1, estimated using formula in Section 5.
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H0 H1
a= 0 a= 1 combined a= 0 a= 1 combined
R2W ;a 0.36 0.34 0.35 0.46 0.30 0.37
R2L;a 0.31 0.30 0.30 0.33 0.26 0.29
R2L|W ;a 0.07 0.08 0.08 0.05 0.07 0.06
R2r;a 0.57 0.58 0.58 0.49 0.63 0.57
Table 2: Empirical R-squared for the data generating distribution based on MISTIE-II.
Columns “combined” are the pooled R-squared.
6.4 Simulation on Relative Efficiency From Variable Adjustment
We conducted simulation studies to validate our theory on asymptotic relative efficiency. To
introduce model misspecification in the simulation, we only adjusted for the baseline variables
(W (1),W (4)) and the short-term outcome L(1). We simulated the delayed response group
sequential design in Section 6.2 with K = 5, nmax = 500, enrollment rate 140 participants
per year, equally spaced interim analyses, dL = 30 days, and dY = 180 days. We assumed no
early stopping here, so that each simulated trial proceeds to the final stage and produces the
unadjusted estimator and TMLE at all 4 interim analyses and all 5 decision analyses for the
three estimands: E(Y |A= 1), E(Y |A= 0), and E(Y |A= 1)−E(Y |A= 0). We simulated
10,000 trials under each of the 4 prognostic settings.
Table 3 lists the theoretical relative efficiency (RE) approximated by Corollary 1 and
Corollary 2, and the empirical relative efficiency from simulation under H0. The correspond-
ing table for H1 is included in Appendix E in the Supplementary Material. It is mostly similar
to Table 3 except for some early stages, at which there is inconsistency between the theory
and simulation results. This inconsistency is likely due to small sample size, misspecified
models in fitting TMLE, and the fact that in the simulation we are estimating the treat-
ment probability and the censoring model. For most settings, RE predicted by the theory is
similar to that from the simulation, indicating that the asymptotic theory approximates the
precision gain quite well, even in the presence of mild model misspecification.
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A comparison between prognW and prognL shows that adjusting for W results in much
larger RE than adjusting for L, which is partly explained by the contrast between (6) and
(7) and partly due to the larger prognostic value in W than in L. Comparing RE under
prognL at interim analysis to that at decision analysis shows that L improves estimation
efficiency only when there are pipeline participants. In addition, we see attenuated efficiency
gain from W and L at later stages.
From interim analysis 1 to 4, the proportion of pipeline participants py gets larger.
As predicted by Corollary 3, the simulated RE under prognW for estimating E(Y |A= a)
decreases at later interim analysis, while the simulated RE under prognW for estimating
E(Y |A= 1)−E(Y |A= 0) is mostly constant at all interim analyses. This is because there
is no treatment effect heterogeneity under H0.
6.5 Simulation on Sample Size Reduction From Variable Adjustment in Group Sequential
Designs
We also conducted simulation studies of the delayed response group sequential design with
early stopping under the four prognostic settings using both the TMLE and the unadjusted
estimator, to assess the reduction in maximum and expected sample sizes. The maximum
sample size nmax was chosen separately for each estimator under each prognostic setting, so
that the design always has approximately 80% power. We adjusted for baseline variables
(W (1),W (4)) and short-term outcome L(1) when fitting TMLE. 10,000 trials were simulated
for each estimator under each prognostic setting. The number of accrued participants, Type
I and Type II errors to spend, and the critical region at each stage are listed in Appendix D
in the Supplementary Material.
Table 4 lists the the nmax, Type I error, power, and the expected sample size (ESS) for
H0 and H1 under each prognostic setting using each estimator. For each row in the table,
Type I error rate is controlled at 0.025 and power is approximately 80% due to the way nmax
22
http://biostats.bepress.com/jhubiostat/paper285
Under H0 RE approximate by Theory RE from Simulation
prognW,L prognW prognL progn∅ prognW,L prognW prognL progn∅
Analysis Estimand: E(Y |A= 1)−E(Y |A= 0)
Interim
1 1.64 1.54 1.12 1.00 1.56 1.47 1.08 0.96
2 1.61 1.54 1.07 1.00 1.55 1.51 1.06 0.98
3 1.60 1.54 1.05 1.00 1.56 1.53 1.04 0.99
4 1.59 1.54 1.04 1.00 1.56 1.52 1.03 0.99
Decision
1 1.57 1.54 1.00 1.00 1.53 1.50 0.99 0.99
2 1.57 1.54 1.00 1.00 1.53 1.53 0.99 0.99
3 1.57 1.54 1.00 1.00 1.53 1.52 0.99 0.99
4 1.57 1.54 1.00 1.00 1.53 1.53 0.99 0.99
5 1.57 1.54 1.00 1.00 1.54 1.53 0.99 0.99
Estimand: E(Y |A= 0)
Interim
1 1.41 1.33 1.13 1.00 1.34 1.28 1.08 0.96
2 1.34 1.29 1.07 1.00 1.29 1.26 1.06 0.99
3 1.31 1.27 1.05 1.00 1.28 1.26 1.05 0.99
4 1.30 1.26 1.04 1.00 1.26 1.26 1.04 0.99
Decision
1 1.24 1.22 1.00 1.00 1.21 1.19 0.99 0.98
2 1.24 1.22 1.00 1.00 1.21 1.21 0.99 0.99
3 1.24 1.22 1.00 1.00 1.21 1.21 1.00 0.99
4 1.24 1.22 1.00 1.00 1.21 1.22 1.00 0.99
5 1.24 1.22 1.00 1.00 1.21 1.22 0.99 0.99
Estimand: E(Y |A= 1)
Interim
1 1.39 1.32 1.12 1.00 1.34 1.29 1.08 0.97
2 1.33 1.28 1.07 1.00 1.28 1.27 1.06 0.98
3 1.30 1.26 1.05 1.00 1.27 1.24 1.04 0.99
4 1.28 1.25 1.04 1.00 1.25 1.23 1.03 0.99
Decision
1 1.23 1.21 1.00 1.00 1.20 1.19 0.99 0.98
2 1.23 1.21 1.00 1.00 1.20 1.19 0.99 0.99
3 1.23 1.21 1.00 1.00 1.20 1.19 0.99 0.99
4 1.23 1.21 1.00 1.00 1.20 1.19 0.99 0.99
5 1.23 1.21 1.00 1.00 1.20 1.19 0.99 0.99
Table 3: Comparison of the relative efficiency (RE) predicted by Corollary 1 and Corollary
2, and the relative efficiency from simulated trials under H0. In the simulation we used a
group sequential design with 5 stages, nmax = 500, enrollment rate 140 participants per year,
equally spaced interim analyses, dL = 30 days, and dY = 180 days. The simulated RE were
based on 10,000 simulated trials. 23
Hosted by The Berkeley Electronic Press
was chosen. ESS is calculated as the number of enrollees when the trial stops, averaging
over 10,000 simulations. The performance of the unadjusted estimator is the same under all
prognostic settings and is summarized in the first row.
Compared to the unadjusted estimator, TMLE reduces both the maximum sample size
and the expected sample size significantly when the baseline variable is prognostic. The
reduction from adjusting for prognostic short-term outcome is limited (comparing prognL
to progn∅ or prognW,L to prognW )—only the expected sample sizes are slighted reduced.
When neither W nor L is prognostic, the performance of the simulated trial using TMLE
is comparable to the trial performance using the unadjusted estimator. Hence, TMLE is
guaranteed to perform as well or better than the unadjusted estimator.
Estimator Progn. set. nmax Type I error Power ESS H0 ESS H1
Unadjusted all 480 0.025 0.81 318 383
TMLE prognW,L 300 0.025 0.80 224 258
prognW 300 0.025 0.80 228 261
prognL 480 0.025 0.80 309 374
progn∅ 480 0.025 0.81 321 384
Table 4: The maximum sample size (nmax), Type I error, Power, and expected sample size
(ESS) under H0 and H1 for each estimator to achieve 80% power under each prognostic
setting (Progn. set.). Columns (except for nmax) are averaged from 10,000 simulated trials.
7 Discussion
If administrative censoring is the only source of missingness, the TMLE and the unadjusted
estimator are both consistent estimators. In a real trial, however, dropouts are likely to
happen, which is another source of missingness in L and Y . If the dropout status only
depends on the observed history (missing at random), TMLE is still consistent under either
correctly modeled dropout distribution or correctly modeled outcome regression, but the
unadjusted estimator can be biased and have inflated Type I error in this case.
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In Section 3 and Section 4 we have focused on the precision gain when using the efficient
RAL estimator. In practice, with an incorrectly specified model the estimator may be
inefficient. A future research area would be to establish a corresponding theory for the
inefficient semiparametric estimators that use misspecified working models.
The progn∅ columns in Table 3 show that at early stages with small sample size, there is
a non-negligible difference between the theoretical RE and the simulated RE: theoretically
adjusting for noise doesn’t hurt RE asymptotically, and in the simulation it hurts slightly
with finite sample size. Such a difference vanishes as the sample size gets larger. One
alternative would be to use the unadjusted estimator at early analyses, and use the adjusted
estimator after a relatively large number of participants has been accrued. The specific rule
for when to switch the choice of estimator would need to be predetermined in the study
protocol, and would need to be accounted for in estimating the covariance of test statistics
at different stages.
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Supplementary Materials
A Causal Framework
For a generic participant, define the potential outcome Y a as the primary outcome that would
have been observed if the participant had been assigned treatment A= a for a∈{0,1}.
Define the average treatment effect θ to be
θ :=E(Y 1)−E(Y 0). (A.1)
We make the following assumptions.
Assumption 1 (Consistency). Y =Y 1A+Y 0(1−A).
Assumption 2 (Randomization). (W,Y 1,Y 0)⊥ A.
Assumption 3 (Missing completely at random). (W,A,L,Y 1,Y 0)⊥ (CL,CY ).
Assumption 4 (Monotone censoring). CL≥CY .
Assumption 1 relates the potential outcome to the observed outcome. Assumption 2
holds in any randomized design. Assumptions 3 and 4 hold if the only source of missingness
in L and Y is administrative censoring.
Under Assumptions 1-4, the average treatment effect is identifiable from the distribution
of the observed data:
E(Y1)−E(Y0) =E[E{E(Y |L,W,A= 1,CY = 1) |W,CL = 1,A= 1}] (A.2)
−E[E{E(Y |L,W,A= 0,CY = 1) |W,CL = 1,A= 0}]
In (A.2), for a∈{0,1} the inner expectation is EY |L,W,A=a,CY =1(·), the mean of Y for the
fully observed participants in arm A= a, within strata of W and L; the middle expectation
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is EL|W,A=a,CL=1{·}, which integrates over the distribution of L for the partially observed par-
ticipants in arm A= a, within strata of W ; the outer expectation is EW [·], which integrates
over the marginal distribution of W in arm A= a. Proof for (A.2) is given as follows.
Proof. It suffices to show that for each a∈{0,1} we have
E(Y a) =E[E{E(Y |L,W,A= a,CY = 1) |W,A= 1,CL = 1}]. (A.3)
Assumptions 1 and 2 imply
E(Y a) =E(Y a |A= a) =E(Y |A= a). (A.4)
Using the law of iterated expectation twice, we deduce
E(Y |A= a) =E[E{E(Y |L,W,A= a) |W,A= a}]. (A.5)
Let f(L,W ) :=E(Y |L,W,A= a). By Assumption 3 we have
E(f(L,W ) |A= a) =E(f(L,W ) |A= a,CL = 1), (A.6)
and
E(Y |L,W,A= a) =E(Y |L,W,A= a,CL = 1,CY = 1). (A.7)
Equations (A.4)-(A.7) together yield
E(Y a) =E[E{E(Y |L,W,A= a,CL = 1,CY = 1) |W,A= 1,CL = 1}]. (A.8)
Equation (A.8) and Assumption 4 yield (A.3). This completes the proof.
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B Details of Group Sequential Design
B.1 Multiple Testing Procedure
In the simulation studies in Section 6 we use the delayed response group sequential test from
Hampson and Jennison (2013) with K stages. Let θ be the true average treatment effect.
Given α,β ∈ (0,1), the design goal is to control Type I error rate at level α and power 1−β at
θ= δ. Such a group sequential test can terminate recruitment at an interim analysis, and if
early stopping happens it waits dY till all pipeline participants become fully observed before
conducting a decision analysis to reject or accept H0. For stage k, denote by Sk and S˜k the
test statistics at interim analysis and decision analysis, respectively; denote by uk and lk the
efficacy and futility boundaries for terminating recruitment at interim analysis, and ck the
critical value for the corresponding decision analysis. The following excerpt from Hampson
and Jennison (2013, Figure 1) illustrates the delayed response group sequential test:
“At interim analysis k= 1,...,K−2,
if Sk≤ lk or Sk≥uk stop recruitment and proceed to decision analysis k;
otherwise continue recruitment and proceed to interim analysis k+1.
At interim analysis K−1,
if SK−1≤ lK−1 or SK−1≥uK−1 stop recruitment and proceed to decision analysis K−1;
otherwise complete recruitment and proceed to decision analysis K.
At decision analysis K,
if S˜K ≥ ck reject H0;
if S˜K <ck accept H0.”
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B.2 Testing Boundaries
Given the Type I error spending function f(·) and the Type II error spending function g(·),
which are non-decreasing with f (0) = g(0) = 0 and f (t) =α and g(t) = β for t≥ 1. The max-
imum information level Imax is chosen depending on the power goal and the error spending
functions. Denote by Ik and I˜k the information levels at the k-th interim analysis and de-
cision analysis, respectively. Denote by Ck = (lk,uk) the critical region at interim analysis k,
1≤ k≤K.
The testing boundaries uk, lk, and ck are calculated following (12)-(15) in Hampson and
Jennison (2013, Section 4.1.1). u1 and l1 are solutions to
P (S1≥u1;θ= 0) = f(I1/Imax) and P (S1≤ l1;θ= δ) = g(I1/Imax).
For 2≤ k≤K−1, uk is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≥uk;θ= 0) = f(Ik/Imax)−f(Ik−1/Imax),
and lk is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≤ lk;θ= δ) = g(Ik/Imax)−g(Ik−1/Imax).
For 1≤ k≤K−1, the critical value ck is the solution to
P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≥uk,S˜k<ck;θ= 0)
=P (S1 ∈C1,...,Sk−1 ∈Ck−1,Sk≤ lk,S˜k≥ ck;θ= 0).
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And the critical value cK for the last stage is the solution to
P (S1 ∈C1,...,SK−1 ∈CK−1,S˜K ≥ cK ;θ= 0) =α−f(IK−1/Imax).
C Resampling-based Algorithm to Simulate Trial Data
For the data generating distribution to have the three properties in Section 6.3, we design the
algorithm to generate a simulated trial of n independent and identically distributed samples
from the 100 participants in MISTIE-II data set as follows.
Step 1: Make treatment assignment independent of baseline variables. We augment the
data with a hypothetical twin for each participant. A twin has identical baseline variables as
the original participant, but opposite treatment assignment. We sample n independent and
identically distributed participants from this augmented data set (100 original participants
and 100 twins), which ensures property (i).
Step 2: Calibrate treatment effect in simulated data. We fit logistic regression models
for L(1) on (W,A), for L(2) on (W,A,L(1)), and for Y on (W,A,L(1),L(2)), using the 100
participants in MISTIE-II data set. The preliminary Li and Yi of each newly added twin
in the n samples are predicted based on these logistic regression models by truncating the
predicted success probability at 0.5. Then, for each newly added twin in the n samples, with
probability 0.03 we reset Yi to equal Ai. This resetting step increases the treatment effect
of the augmented data to 0.122, matching that of the original data. Now, sampling with
replacement from this augmented data set ensures properties (i) and (ii).
Step 3: Calibrate relative efficiency of TMLE. For a∈{0,1}, we empirically estimate
pa :=P (Y = 1 |A= a) using the original data. Then, for each newly added twin in the n
samples, with probability 0.164 we reset Yi by a realization of Bernoulli random variable
with success probability pAi . This resetting step adds random noise to reduce the prognostic
value in W and L. Meanwhile it keeps the treatment effect of the augmented data unchanged.
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Table 5 displays the relative efficiency between TMLE and the unadjusted estimator in the
original data, in the augmented data before Step 3, and in the augmented data after Step 3,
when the trial sample size and timing are as in the first simulation study in Section 6.4.
Relative efficiency
Original data
Augmented data
before step 3 after step 3
stage 1 1.54 1.74 1.52
stage 2 1.53 1.74 1.55
stage 3 1.54 1.75 1.55
stage 4 1.55 1.76 1.55
stage 5 1.55 1.75 1.55
Table 5: Relative efficiency between TMLE and the unadjusted estimator, where the trial
sample size and timing are as in the first simulation study in Section 6.4.
D Example design
Table 6 lists the sample size and analysis timing of the group sequential designs with nmax =
480 and nmax = 300 used in Section 6.4. For 1≤ k≤ 4, Analysis k indicates interim analysis
at stage k and k∗ indicates the corresponding decision analysis if enrollment is early stopped
at that stage. Analysis 5∗ indicates the final decision analysis. Note that there is not interim
analysis for the final stage. Fully observed participants are those with W,L,Y observed;
partially observed participants are those with W,L but not Y observed. The three groups of
participants listed in Table 6 are inclusive of all enrollees and mutually exclusive.
Table 7 lists the Type I error and Type II error spent and the testing boundaries at each
stage for the designs under prognostic setting prognW,L, where nmax = 480 for the unadjusted
estimator and nmax = 300 for TMLE. We use error spending functions f(t) = 0.025min(t
2,1)
and g(t) = 0.2min(t2,1). Boundaries uk,lk,ck are computed following Section B.
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Analysis 1 1∗ 2 2∗ 3 3∗ 4 4∗ 5∗
nmax = 480
Time (year) 1.2 1.7 1.9 2.4 2.6 3.0 3.2 3.7 3.9
# Fully observed (W,L,Y ) 96 165 192 261 288 357 384 453 480
# Partially observed (W,L) 57 0 57 0 57 0 57 0 0
# Pipeline with only W observed 12 0 12 0 12 0 12 0 0
nmax = 300
Time (year) 0.9 1.4 1.4 1.8 1.8 2.3 2.2 2.6 2.6
# Fully observed (W,L,Y ) 60 129 120 189 180 249 240 300 300
# Partially observed (W,L) 57 0 57 0 57 0 57 0 0
# Pipeline with only W observed 12 0 12 0 12 0 3 0 0
Table 6: Analysis time and sample size at each interim and decision analysis for group
sequential designs with nmax = 480 and nmax = 300. For 1≤ k≤ 4, Analysis k indicates interim
analysis and k∗ indicates the corresponding decision analysis if enrollment is early stopped.
Analysis 5∗ indicates the final decision analysis.
Analysis 1 2 3 4 5
TMLE nmax = 300
Type I error to spend (×10−3) 0.9 3.1 5.0 7.5 8.4
Type II error to spend (×10−3) 7.6 24.6 40.4 60.3 67.2
Efficacy boundary at interim analysis (uk) 3.12 2.72 2.48 2.26 -
Futility boundary at interim analysis (lk) -0.66 0.32 1.04 1.68 -
Critical value at decision analysis (ck) 1.65 1.76 1.91 2.03 1.96
Unadjusted estimator nmax = 480
Type I error to spend (×10−3) 1.0 3.0 4.9 7.3 8.8
Type II error to spend (×10−3) 8.2 24.4 39.3 58.0 70.2
Efficacy boundary at interim analysis (uk) 3.08 2.72 2.47 2.25 -
Futility boundary at interim analysis (lk) -1.08 -0.04 0.74 1.44 -
Critical value at decision analysis (ck) 1.25 1.50 1.72 1.93 2.05
Table 7: Error spending and boundaries for designs in Section 6.4 under prognostic setting
prognW,L.
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E Simulation Results for Relative Efficiency Under H1
See Table 8 for the simulation results for relative efficiency under H1. This is supplementary
to the simulation results presented in Table 3 of Section 6.4.
F Proof of Main Theorems
F.1 Proof of Lemma 1
Proof. Adding and subtracting terms, we have
Vara(Y ) = Vara
[{Y −Ea(Y |L,W )}+{Ea(Y |L,W )−Ea(Y |W )}+Ea(Y |W )]. (A.9)
So for proving (2), it suffices to establish the following:
Cova
{
Y −Ea(Y |L,W ),Ea(Y |L,W )−Ea(Y |W )
}
= 0, (A.10)
Cova
{
Y −Ea(Y |L,W ),Ea(Y |W )
}
= 0, (A.11)
Cova
{
Ea(Y |L,W )−Ea(Y |W ),Ea(Y |W )
}
= 0, (A.12)
where Cova denotes the conditional covariance given A= a.
First, we have
Cova
{
Y −Ea(Y |L,W ),Ea(Y |L,W )−Ea(Y |W )
}
=Ea
{
Y Ea(Y |L,W )−Ea(Y |L,W )2−Y Ea(Y |W )+Ea(Y |L,W )Ea(Y |W )
}
. (A.13)
By Lemma 6 with X =Z = (L,W ), we have
Ea
{
Y Ea(Y |L,W )
}
=Ea
{
Ea(Y |L,W )2
}
. (A.14)
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Under H1 RE approximated by Theory RE from Simulation
prognW,L prognW prognL progn∅ prognW,L prognW prognL progn∅
Analysis Estimand: E(Y |A= 1)−E(Y |A= 0)
Interim
1 1.71 1.58 1.12 1.00 2.44 1.51 1.58 0.96
2 1.68 1.57 1.07 1.00 1.96 1.55 1.26 0.98
3 1.67 1.57 1.05 1.00 1.84 1.57 1.18 0.99
4 1.66 1.57 1.04 1.00 1.74 1.57 1.14 1.00
Decision
1 1.64 1.57 1.00 1.00 1.53 1.55 0.99 0.99
2 1.64 1.57 1.00 1.00 1.53 1.56 0.99 1.00
3 1.64 1.57 1.00 1.00 1.53 1.58 1.00 1.00
4 1.64 1.57 1.00 1.00 1.53 1.57 1.00 1.00
5 1.64 1.57 1.00 1.00 1.52 1.56 1.00 1.00
Estimand: E(Y |A= 0)
Interim
1 1.67 1.48 1.14 1.00 2.11 1.47 1.56 0.97
2 1.56 1.41 1.08 1.00 1.67 1.42 1.27 0.99
3 1.52 1.38 1.06 1.00 1.56 1.39 1.20 0.99
4 1.49 1.36 1.04 1.00 1.47 1.38 1.15 0.99
Decision
1 1.41 1.30 1.00 1.00 1.29 1.32 0.99 0.99
2 1.41 1.30 1.00 1.00 1.29 1.33 1.00 0.99
3 1.41 1.30 1.00 1.00 1.29 1.32 1.00 1.00
4 1.41 1.30 1.00 1.00 1.30 1.33 1.00 1.00
5 1.41 1.30 1.00 1.00 1.30 1.33 1.00 1.00
Estimand: E(Y |A= 1)
Interim
1 1.31 1.27 1.11 1.00 1.83 1.22 1.56 0.97
2 1.26 1.23 1.06 1.00 1.52 1.21 1.26 0.98
3 1.24 1.22 1.04 1.00 1.40 1.20 1.18 0.99
4 1.22 1.21 1.03 1.00 1.33 1.20 1.14 0.99
Decision
1 1.18 1.18 1.00 1.00 1.16 1.16 0.99 0.99
2 1.18 1.18 1.00 1.00 1.16 1.16 0.99 0.99
3 1.18 1.18 1.00 1.00 1.16 1.17 0.99 1.00
4 1.18 1.18 1.00 1.00 1.15 1.16 1.00 1.00
5 1.18 1.18 1.00 1.00 1.15 1.16 1.00 1.00
Table 8: Comparison of relative efficiency implied by theory in Section 3 and relative effi-
ciency calculated from simulated trials, under H1 of the data generating distribution based
on MISTIE-II. We consider a group sequential design with 5 stages, nmax = 500, enrollment
rate 140 participants per year, equally spaced interim analyses, dL = 30 days, and dY = 180
days. The simulation results are based on 10,000 simulated trials.37
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By Lemma 6 with X =W and Z = (L,W ), we have
Ea
{
Y Ea(Y |W )
}
=Ea
{
Ea(Y |L,W )Ea(Y |W )
}
. (A.15)
Equations (A.13), (A.14), and (A.15) imply (A.10).
Second, we have
Cova
{
Y −Ea(Y |L,W ),Ea(Y |W )
}
=Ea
{
Y Ea(Y |W )−Ea(Y |L,W )Ea(Y |W )
}
. (A.16)
Equations (A.16) and (A.15) imply (A.11).
Third, since Ea(Y |L,W )−Ea(Y |W ) has expectation zero, we have
Cova
{
Ea(Y |L,W )−Ea(Y |W ),Ea(Y |W )
}
=Ea
{
Ea(Y |L,W )Ea(Y |W )−Ea(Y |W )2
}
.
(A.17)
In Lemma 6, letting X =Z =W and replacing Y in the lemma by E(Y |L,W ) implies
Ea
{
Ea(Y |L,W )Ea(Y |W )
}
=Ea
{
Ea(Y |W )2
}
. (A.18)
Equations (A.17) and (A.18) imply (A.12).
This proves (2). Equation (4) follows immediately from (2) and the definition of R2W and
R2r . This completes the proof for Lemma 1.
F.2 Proof of Theorem 2
Proof. Equations (A.4) and (A.8) yield
E(Y |A= a) =E[E{E(Y |L,W,A= a,CL = 1,CY = 1) |W,A= 1,CL = 1}]. (A.19)
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Treating the missingness indicators CL and CY as binary treatments, the right-hand side
of (A.19) becomes the average of outcome Y under time dependent treatment assignment:
A= a,CL = 1,CY = 1. Because there is no measurement made between A and CL, we can
combine the two as a single treatment A˜, with A˜= 1 if and only if A= a and CL = 1. Equation
(A.19) becomes
E(Y |A= a) =E[E{E(Y |L,W,A˜= 1,CY = 1) |W,A˜= 1}]. (A.20)
Using the fact that L is binary-valued, by equations (24) and (28) in Rosenblum and van der
Laan (2011) or Theorem 1 in van der Laan (2010), the efficient influence function for (A.20)
is
D(W,A˜,L,CY ,Y ) =D0(W )+D1(W,A˜,L)+D2(W,A˜,L,C
Y ,Y ), (A.21)
where
D0(W ) =E(Y |W,A˜= 1,CY = 1)−E(Y | A˜= 1), (A.22)
D1(W,A˜,L) =
1(A˜= 1)
{
E(Y |L,W,A˜= 1,CY = 1)−E(Y |W,A˜= 1,CY = 1)}
P (A˜= 1 |W ) , (A.23)
and
D2(W,A˜,L,C
Y ,Y ) =
1(CY = 1)1(A˜= 1)
{
Y −E(Y |L,W,A˜= 1,CY = 1)}
P (CY = 1 |L,W,A˜= 1)P (A˜= 1 |W ) . (A.24)
By randomization and independent censoring assumptions, (A.22) simplifies to
D0(W ) =E(Y |W,A= a)−E(Y |A= a); (A.25)
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equation (A.23) simplifies to
D1(W,A˜,L) =
1(A˜= 1)
{
E(Y |L,W,A= a)−E(Y |W,A= a)}
P (A˜= 1)
; (A.26)
equation (A.24) simplifies to
D2(W,A˜,L,C
Y ,Y ) =
1(CY = 1)1(A˜= 1)
{
Y −E(Y |L,W,A= a)}
P (CY = 1 |CL = 1)P (A˜= 1) . (A.27)
The following lemma states that D0, D1, and D2 are pairwise uncorrelated.
Lemma 4. We have
Cov{D0(W ),D1(W,A˜,L)}= 0, (A.28)
Cov{D0(W ),D2(W,A˜,L,CY ,Y )}= 0, (A.29)
Cov{D1(W,A˜,L),D2(W,A˜,L,CY ,Y )}= 0. (A.30)
Lemma 4 implies
Var{D(W,A˜,L,CY ,Y )}= Var{D0(W )}+Var{D1(W,A˜,L)}+Var{D2(W,A˜,L,CY ,Y )}.
(A.31)
By (A.25) we have
Var{D0(W )}= Var{Ea(Y |W )}= Vara{Ea(Y |W )}, (A.32)
where the last equality follows from randomization assumption. By (A.26) we have E{D1(W,A˜,L)}=
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0, so it follows from randomization and independent censoring that
Var{D1(W,A˜,L)}=E
[1(A˜= 1)2{E(Y |L,W,A= a)−E(Y |W,A= a)}2
P (A˜= 1)2
]
=
E{1(A˜= 1)}
P (A˜= 1)2
E
[{
E(Y |L,W,A= a)−E(Y |W,A= a)}2 |A= a].
(A.33)
By independent censoring we have P (A˜= 1) = papl. It then follows from (A.33) and random-
ization assumption that
Var{D1(W,A˜,L)}= 1
papl
Vara
{
Ea(Y |L,W )−Ea(Y |W )
}
. (A.34)
Similarly, (A.27) together with randomization and monotone censoring imply
Var{D2(W,A˜,L,CY ,Y )}= 1
papy
Vara
{
Y a−Ea(Y |L,W )
}
. (A.35)
Because the semiparametric lower bound on the asymptotic variance for an estimand
equals the variance of the efficient influence function, by (A.31), (A.32), (A.34), and (A.35)
we proved Theorem 2.
F.3 Proof of Corollary 1
Proof. For notation simplicity, let CYi stand for (C
Y )i, the censoring indicator of Y for
participant i. The unadjusted estimator τˆ for E(Y |A= a) is defined as
τˆ =
∑n
i=1Yi1(Ai = a,CYi = 1)∑n
i=11(Ai = a,CYi = 1)
. (A.36)
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Using the causal framework in Section A, (A.36) becomes
τˆ =
∑n
i=1Y
a
i 1(Ai = a,CYi = 1)∑n
i=11(Ai = a,CYi = 1)
. (A.37)
Under Assumptions 2 and 3 in Section A, τˆ is unbiased:
E(τˆ) =E
[
E
{∑n
i=1Y
a
i 1(Ai = a,CYi = 1)∑n
i=11(Ai = a,CYi = 1)
∣∣∣A1,...,An,CY1 ,...,CYn}]=E(Y a). (A.38)
In the following we calculate the asymptotic variance of τˆ .
√
n{τˆ−E(Y a)}=
1√
n
∑n
i=1Y
a
i 1(Ai = a,CYi = 1)
1
n
∑n
i=11(Ai = a,CYi = 1)
−√nE(Y a)
=
1√
n
∑n
i=1{Y ai −E(Y a)}1(Ai = a,CYi = 1)
1
n
∑n
i=11(Ai = a,CYi = 1)
. (A.39)
By Weak Law of Large Numbers and the independent censoring assumption,
1
n
n∑
i=1
1(Ai = a,CYi = 1)
P→ papy, (A.40)
where
P→ denotes convergence in probability. By Central Limit Theorem,
1√
n
n∑
i=1
{Y ai −E(Y a)}1(Ai = a,CYi = 1) d→N(0,σ2), (A.41)
where by randomization and independent censoring we have
σ2 = Var
[{Y a−E(Y a)}1(A= a,CY = 1)]=E[{Y a−E(Y a)}21(A= a,CY = 1)2]
= papyVar(Y
a). (A.42)
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Combining (A.39)-(A.42), it follows from Slutsky’s theorem that
√
n{τˆ−E(Y a)} d→N(0,(papy)−1Var(Y a)).
So the asymptotic variance of τˆ is (papy)
−1Var(Y a), which by randomization yields
AVar(unadjusted) =
1
papy
Vara(Y ). (A.43)
Equations (A.43) and (4) imply
AVar(unadjusted) =
1
papy
Vara(Y )(R
2
W ;a+R
2
L|W ;a+R
2
r;a). (A.44)
On the other hand, Theorem 2 and the definition of R2W and R
2
r imply
AVar(efficient) = Vara(Y )(R
2
W ;a+
1
papl
R2L|W ;a+
1
papy
R2r;a). (A.45)
Equations (A.44) and (A.45) yield (5).
Equation (6) follows immediately from (5). For (7), note that if R2W ;a = 0, by definition
we have R2L|W ;a =R
2
L;a. So (7) follows from (5). The proof is thus finished.
F.4 Proof of Theorem 3
For notation simplicity, denote by Q(·) the conditional expectation E(Y | ·). Using the
derivation in (A.19)-(A.27) twice for A= 1 and A= 0, we get the efficient influence function
D(W,A,CL,L,CY ,Y ) for E(Y |A= 1)−E(Y |A= 0):
D(W,A,CL,L,CY ,Y ) =D0(W )+D1(W,A,C
L,L)+D2(W,A,C
L,L,CY ,Y ), (A.46)
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where
D0(W ) =
{
Q(W,A= 1)−Q(A= 1)}−{Q(W,A= 0)−Q(A= 0)}, (A.47)
D1(W,A,C
L,L) =
ACL
p1pl
{
Q(W,L,A= 1)−Q(W,A= 1)}
− (1−A)C
L
p0pl
{
Q(W,L,A= 0)−Q(W,A= 0)}, (A.48)
and
D2(W,A,C
L,L,CY ,Y ) =
ACY
p1py
{
Y −Q(W,L,A= 1)}− (1−A)CY
p0py
{
Y −Q(W,L,A= 0)}.
(A.49)
The following lemma states that D0, D1, and D2 are pairwise uncorrelated.
Lemma 5. We have
Cov{D0(W ),D1(W,A,CL,L)}= 0, (A.50)
Cov{D0(W ),D2(W,A,CL,L,CY ,Y )}= 0, (A.51)
Cov{D1(W,A,CL,L),D2(W,A,CL,L,CY ,Y )}= 0. (A.52)
Lemma 5 implies
Var{D(W,A,CL,L,CY ,Y )}=Var{D0(W )}+Var{D1(W,A,CL,L)}
+Var{D2(W,A,CL,L,CY ,Y )}. (A.53)
By A.47 we have
Var{D0(W )}= Var{Q(W,A= 1)−Q(W,A= 0)}. (A.54)
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By (A.48) we have
Var{D1(W,A,CL,L)}=E
[ACL
p21p
2
l
{
Q(W,L,A= 1)−Q(W,A= 1)}2]
+E
[(1−A)CL
p20p
2
l
{
Q(W,L,A= 0)−Q(W,A= 0)}2] (A.55)
=
∑
a∈{0,1}
1
papl
E
[{
Q(W,L,A= a)−Q(W,A= a)}2 |A= a] (A.56)
=
∑
a∈{0,1}
1
papl
Var
{
Q(W,L,A= a)−Q(W,A= a) |A= a}. (A.57)
The step from (A.55) to (A.56) utilizes the independent censoring and randomization as-
sumptions. Similarly, (A.49) together with randomization and independent censoring imply
Var{D2(W,A,CL,L,CY ,Y )}=
∑
a∈{0,1}
1
papl
Var
{
Y −Q(W,L,A= a) |A= a}. (A.58)
Because the semiparametric lower bound on the asymptotic variance for an estimand
equals the variance of the efficient influence function, by (A.53), (A.54), (A.57), and (A.58)
we proved Theorem 3.
F.5 Proof of Corollary 2
The unadjusted estimator for the average treatment effect is
τˆ =
∑n
i=1Yi1(Ai = 1,CYi = 1)∑n
i=11(Ai = 1,CYi = 1)
−
∑n
i=1Yi1(Ai = 0,CYi = 1)∑n
i=11(Ai = 0,CYi = 1)
.
Similar to the derivation from (A.36) to (A.43), when estimating the average treatment effect
with P (A= 1) =P (A= 0) = 1/2, we have
AVar(unadjusted) =
1
0.5py
∑
a∈{0,1}
Vara(Y ). (A.59)
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The result in Corollary 2 then follows immediately from Theorem 3.
F.6 Proof of Corollary 3
(i) Purely predictive baseline variable. Because
Var{E(Y |W )}= Var{0.5E(Y |W,A= 1)+0.5E(Y |W,A= 1)},
Var{E(Y |W )}= 0 implies
Var{E(Y |W,A= 1)}+Var{E(Y |W,A= 0)}=−2Cov{E(Y |W,A= 1),E(Y |W,A= 0).
(A.60)
By (A.60) and the definition of γ and R2W , we have γ= 2R
2
W . This combined with (12) imply
(14).
(ii) Purely prognostic baseline variable. By the definition of γ and Var{E(Y |W,A=
1)−E(Y |W,A= 0)}= 0, (15) follows immediately from (12).
G Proof of Auxiliary Lemmas
G.1 Additional Supporting Lemmas
Lemma 6. Consider three random variables X, Y , and Z. Denote by σ(Z) the σ-field
generated by Z. If X ∈σ(Z), then
E
{
Y E(Y |X)}=E{E(Y |Z)E(Y |X)}. (A.61)
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Proof. By the law of iterated expectation, we have
E
{
Y E(Y |X)}=E[E{Y E(Y |X) |Z}]. (A.62)
Because X ∈σ(Z), we have E(Y |X)∈σ(X)⊂σ(Z). This implies
E
{
Y E(Y |X) |Z}=E(Y |X)E(Y |Z). (A.63)
Equations (A.62) and (A.63) imply (A.61). This completes the proof.
Lemma 7. Consider three random variables W , L, and Y . For any measurable functions
f(W ) and g(W,L), we have
E
[
f(W )
{
E(Y |W,L)−E(Y |W )}]= 0, (A.64)
E
[
g(W,L)
{
Y −E(Y |W,L)}]= 0. (A.65)
Proof. By the law of iterated expectation, we have
E
{
g(W )E(Y |W,L)}=E[E{g(W )E(Y |W,L) |W}]
=E
[
g(W )E
{
E(Y |W,L) |W}]
=E
{
g(W )E(Y |W )},
which proves (A.64).
Similarly, we have
E
{
g(W,L)Y
}
=E
[
E
{
g(W,L)Y |W,L}]=E{g(W,L)E(Y |W,L)},
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which proves (A.65).
G.2 Proof of Lemma 4
Proof. By (A.25) and (A.26) we have
Cov(D0,D1)∝E
[
1(A˜= 1){Ea(Y |W )−Ea(Y )}{Ea(Y |L,W )−Ea(Y |W )}
]
. (A.66)
Combining (A.12), (A.66), and Assumptions 2-3, we derive (A.28).
By (A.25) and (A.27) we have
Cov(D0,D2)∝E
[
1(A˜= 1,CY = 1){Ea(Y |W )−Ea(Y )}{Y −Ea(Y |L,W )}
]
. (A.67)
Combining (A.11), (A.67), and Assumptions 2-3, we derive (A.29).
By (A.26) and (A.27) we have
Cov(D1,D2)∝E
[
1(A˜= 1,CY = 1){Ea(Y |L,W )−Ea(Y |W )}{Y −Ea(Y |L,W )}
]
. (A.68)
Combining (A.10), (A.68), and Assumptions 2-3, we derive (A.30).
This completes the proof.
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G.3 Proof of Lemma 5
For notation simplicity, we use E1(·) and E0(·) to denote E(· |A= 1) and E(· |A= 0), re-
spectively. By (A.47) and (A.48) we have
Cov(D0,D1)∝E
[
A
{
Q(W,A= 1)−Q(W,A= 0)}{Q(W,L,A= 1)−Q(W,A= 1)}]
−E[(1−A){Q(W,A= 1)−Q(W,A= 0)}{Q(W,L,A= 0)−Q(W,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
E1(Y |W )−E0(Y |W )
}{
Ea(Y |W,L)−Ea(Y |W )
}×P (A= a).
(A.69)
Both terms in (A.69) equals 0 by (A.64) in Lemma 7 with f(W ) =E1(Y |W )−E0(Y |W ).
This yields (A.50).
By (A.47) and (A.49) we have
Cov(D0,D2)∝E
[
A
{
Q(W,A= 1)−Q(W,A= 0)}{Y −Q(W,L,A= 1)}]
−E[(1−A){Q(W,A= 1)−Q(W,A= 0)}{Y −Q(W,L,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
E1(Y |W )−E0(Y |W )
}{
Y −Ea(Y |W,L)
}×P (A= a).
(A.70)
Both terms in (A.70) equals 0 by (A.65) in Lemma 7 with g(W,L) =E1(Y |W )−E0(Y |W ).
This yields (A.51).
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By (A.48) and (A.49) we have
Cov(D1,D2)∝E
[
A
{
Q(W,L,A= 1)−Q(W,A= 1)}{Y −Q(W,L,A= 1)}]
−E[(1−A){Q(W,L,A= 0)−Q(W,A= 0)}{Y −Q(W,L,A= 0)}]
=
∑
a∈{0,1}
Ea
[{
Ea(Y |W,L)−Ea(Y |W )
}{
Y −Ea(Y |W,L)
}×P (A= a).
(A.71)
Both terms in (A.71) equals 0 by (A.65) in Lemma 7 with g(W,L) =Ea(Y |W,L)−Ea(Y |W ).
This yields (A.52).
This completes the proof.
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